Quantification of Myocardial Fibrosis in Aortis Stenosis

Launched by NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY · Aug 23, 2024

Keywords

ClinConnect Summary

This clinical trial is looking at how heart muscle changes over time in patients with aortic valve stenosis, a condition where the heart's aortic valve becomes narrowed, affecting blood flow. The study will follow up with patients who were part of an earlier study, where they underwent various tests like heart ultrasounds and MRIs to measure heart function and quality of life. Now, after several years, researchers will repeat these tests to see how the heart muscle has changed, particularly focusing on a condition known as myocardial fibrosis, which is the thickening of heart tissue that can affect heart function.

To be eligible for this trial, participants need to have been part of the initial study and still be able to complete the required tests. This includes patients with mild, moderate, or severe aortic stenosis. Those with certain health issues, like severe kidney problems or other significant heart diseases, may not be able to participate. If enrolled, participants can expect to undergo similar heart imaging and tests they had before, helping researchers understand how their condition has progressed over time. This study aims to provide valuable insights that could improve care for patients with aortic valve stenosis in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Part of the initial cohort that were included in the baseline study
• • Still able to undergo protocolled investigations
• • Patients: Mild, moderate or severe AS
• Exclusion Criteria:
• • Renal insufficiency
• • Previously myocardial infarction (ECG, echocardiogram or hospital record)
• • Severe valvular heart disease (except patients)
• • Other cardiac disease known to cause myocardial fibrosis
• • Severe hypertension
• • Other medical conditions deterring protocolled investigation and follow-up
• • Other medical conditions affecting 5-years prognosis (cancer, pulmonary disease)
• • Severely reduced image-quality (echocardiography and MRI)